Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9095803 | 0.88 | ALDH1A1 (0.41) | ALDH1A1LMNATSHRCES2CES1 | |
| SCHEMBL7439608 | 0.86 | TSHR (0.33) | TSHR | |
| SCHEMBL8154444 | 0.86 | DGKA (0.47) | ALDH1A1LMNATSHRCES2CES1 | |
| SCHEMBL8945612 | 0.84 | DGKA (0.50) | ALDH1A1LMNATSHRCES2CES1 | |
| SCHEMBL3216527 | 0.84 | DGKA (0.50) | ALDH1A1LMNATSHRCES2CES1 | |
| SCHEMBL9400193 | 0.84 | DGKA (0.50) | ALDH1A1LMNATSHRCES2CES1 | |
| SCHEMBL8945727 | 0.84 | DGKA (0.50) | ALDH1A1LMNATSHRCES2CES1 | |
| SCHEMBL8527978 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL8528903 | 0.81 | TSHR (0.54) | ALDH1A1LMNATSHR | |
| SCHEMBL11257758 | 0.79 | ALDH1A1 (0.52) | ALDH1A1LMNATSHRCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550607-B2 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | AUSPEX PHARMACEUTICAL, INC. (US) | 2009-06-23 | — | — | US | claimed |
| EP-1594835-A4 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS INC (US) | 2007-05-02 | — | — | EP | claimed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | claimed |
| EP-1594835-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | Auspex Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| JP-5137584-A | — | — | None | — | — | JP | disclosed |
| EP-2998288-B1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARM INC (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-03-29 | — | — | US | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-11-03 | — | — | US | disclosed |
| WO-1991007501-A1 | ENZYMATIC RESOLUTION OF ENDO-BICYCLO[2.2.1]HEPTAN-2-OL AND DERIVED PHARMACEUTICAL AGENTS | PFIZER INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| WO-1991007177-A1 | PYRIMIDONE DERIVATIVES AND ANALOGS IN THE TREATMENT OF ASTHMA OR CERTAIN SKIN DISORDERS | PFIZER INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| EP-0428302-A2 | Enzymatic resolution of endo-bicycle(2.2.1)-heptan-2-ol and derived pharmaceutical agents | PFIZER INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0428313-A2 | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders | PFIZER INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| US-4933290-A | REACTING WITH AN ESTER, ACID, OR ANHYDRIDE IN THE PRESENCE OF A LIPASE IMMOBILIZED ON A POROUS CARRIER | MONTEDISON S.P.A. (IT) | 1990-06-12 | — | — | US | disclosed |
| EP-0304706-A2 | Process for producing optically active compounds having pyridine skeletons | CHISSO CORPORATION (JP) | 1989-03-01 | — | — | EP | disclosed |
| EP-0288994-A2 | Process for producing optically active compounds | Chisso Corporation (JP) | 1988-11-02 | — | — | EP | disclosed |
| EP-0274277-A2 | A process for the enzymatic separation of the optical isomers of racemic oxazolidinonic derivatives | Montedison S.p.A. (IT) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | ALDH1A1 3075/4885LMNA 869/4885TSHR 847/4885 |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | ALDH1A1 3075/4885LMNA 869/4885TSHR 847/4885 |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ALDH1A1 3075/4885LMNA 869/4885TSHR 847/4885 |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ALDH1A1 3075/4885LMNA 869/4885TSHR 847/4885 |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | LSS, DHPS, CYP51A1 | ALDH1A1 1435/4885LMNA 1693/4885TSHR 3358/4885 |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | ALDH1A1 3075/4885LMNA 869/4885TSHR 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.